• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by enVVeno Medical Corporation

    2/14/24 4:51:40 PM ET
    $NVNO
    Medical/Dental Instruments
    Health Care
    Get the next $NVNO alert in real time by email
    SC 13G 1 tm243309d29_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    enVVeno Medical Corporation

    (Name of Issuer)

     

    Common Stock, $0.00001 par value

    (Title of Class of Securities)

     

    29415J106

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

     

    CUSIPNO. 29415J106  Page 2 of 7

     

    CUSIP No.  29415J106
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,399,588
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,399,588
    (9) Aggregate amount beneficially owned by each reporting person 1,399,588
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIPNO. 29415J106  Page 3 of 7

     

    CUSIP No.  29415J106
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,399,588
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,399,588
    (9) Aggregate amount beneficially owned by each reporting person 1,399,588
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIPNO. 29415J106  Page 4 of 7

     

    CUSIP No.  29415J106
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 1,399,588
    (7) Sole dispositive power 0
    (8) Shared dispositive power 1,399,588
    (9) Aggregate amount beneficially owned by each reporting person 1,399,588
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 9.9%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      enVVeno Medical Corporation (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      70 DOPPLER, IRVINE, CA 92618
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.00001 par value (the “Shares”). 

     

     

     

     

    CUSIPNO. 29415J106  Page 5 of 7

     

    Item 2(e).

    CUSIP Number:
     

     

    29415J106

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 1,399,588 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 1,399,588 Shares includes 693,269 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 9.9% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed October 26, 2023, there were 13,317,000 Shares outstanding in addition to the 693,269 Shares issuable upon the exercise of the warrants).

     

     

     

     

    CUSIPNO. 29415J106  Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

     
      (i) Sole power to vote or direct the vote 0  
      (ii) Shared power to vote or to direct the vote 1,399,588  
      (iii) Sole power to dispose or to direct the disposition of 0  
      (iv) Shared power to dispose or to direct the disposition of 1,399,588  
     

    Each of Messrs. Harkey and Mack

     
      (i) Sole power to vote or direct the vote 0  
      (ii) Shared power to vote or to direct the vote 1,399,588  
      (iii) Sole power to dispose or to direct the disposition of 0  
      (iv) Shared power to dispose or to direct the disposition of 1,399,588  
       
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      BLACKWELL PARTNERS LLC - SERIES A, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of more than five percent of the outstanding shares of common stock beneficially owned by Nantahala reported herein.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

     

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIPNO. 29415J106  Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By: /s/ Taki Vasilakis
      Taki Vasilakis
      Chief Compliance Officer
       
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $NVNO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVNO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVNO
    Financials

    Live finance-specific insights

    See more
    • enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

      85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

      11/20/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

      Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application

      11/19/24 8:15:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical to Host Conference Call and Webcast on September 21, 2022

      - Conference call with live audio webcast to be held on Wednesday, September 21st at 4:30 PM ETIRVINE, CA / ACCESSWIRE / September 19, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it will host a conference call and webcast on Wednesday, September 21, 2022 at 4:30 PM ET.Interested participants and investors may access the conference call by dialing (877) 407-9708 (domestic) or (201) 689-8259 (international) and referencing conference ID: 13732870. The live webcast will be accessible on the Events page of the Investors section of the enVVeno website, envveno.com, and w

      9/19/22 8:05:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    SEC Filings

    See more
    • enVVeno Medical Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      5/20/25 4:30:22 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by enVVeno Medical Corporation

      10-Q - enVVeno Medical Corp (0001661053) (Filer)

      4/30/25 5:28:15 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - enVVeno Medical Corp (0001661053) (Filer)

      4/21/25 4:05:32 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

      Successful Completion of All Planned Implants in GLP StudyenVVe Delivery System Demonstrates Consistent PerformanceCompany Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-t

      12/16/24 8:50:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

      Interviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess the Recap Website Here!IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. Materials accessible on the recap website include interviews with two patients and

      11/27/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

      85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97% Target Vein Patency RateImprovement in All Patient Reported Quality-of-Life IndicatorsCompany to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st A

      11/20/24 8:30:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

      SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

      11/14/24 4:50:32 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by enVVeno Medical Corporation (Amendment)

      SC 13G/A - enVVeno Medical Corp (0001661053) (Subject)

      2/23/24 4:16:05 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by enVVeno Medical Corporation

      SC 13G - enVVeno Medical Corp (0001661053) (Subject)

      2/14/24 4:51:40 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Leadership Updates

    Live Leadership Updates

    See more
    • enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

      Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024IRVINE, CA / ACCESSWIRE / April 9, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Andrew Cormack has been hired as the Company's Chief Commercial Officer. Mr. Cormack, who joined enVVeno Medical on April 8, comes to enVVeno following a career at both start-up and large medical device companies including WallabyPhenox, Medtronic, Covidien,

      4/9/24 8:45:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations

      IRVINE, CA / ACCESSWIRE / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at Medtronic.Mr. Belteau joined Medtronic as a field engineer upon graduation from college and has progressed through various clinical operations roles over the course of his tenure there. Most recently he managed his own team of clinical operations professionals and has been directly involved is more than 75 clinical st

      8/16/22 8:05:00 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Bright Jennifer

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      5/20/25 4:40:04 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Bright Jennifer

      3 - enVVeno Medical Corp (0001661053) (Issuer)

      5/20/25 4:35:31 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Duhay Francis bought $249,999 worth of shares (81,433 units at $3.07), increasing direct ownership by 389% to 102,344 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/3/25 7:00:20 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care

    $NVNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duhay Francis bought $249,999 worth of shares (81,433 units at $3.07), increasing direct ownership by 389% to 102,344 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/3/25 7:00:20 AM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Gray Robert bought $10,290 worth of shares (3,500 units at $2.94), increasing direct ownership by 46% to 11,155 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      1/2/25 4:05:22 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care
    • Director Shrivastava Sanjay bought $15,660 worth of shares (5,400 units at $2.90), increasing direct ownership by 139% to 9,288 units (SEC Form 4)

      4 - enVVeno Medical Corp (0001661053) (Issuer)

      12/26/24 4:30:21 PM ET
      $NVNO
      Medical/Dental Instruments
      Health Care